Navigating complexity: The Supera's triumph in femoropopliteal lesions

CONCLUSIONS: The 36-month patency of the Supera stents in our real-world cohort was similar to other reported series. The GLASS stage did not interfere with the stent patency, proving it is a good choice even in the most adverse anatomy patients. Only the non-nominal stent conformation affected the primary patency rates in our patients.PMID:38588331 | DOI:10.1177/17085381241246321
Source: Vascular - Category: Surgery Authors: Source Type: research